Additionally, multiple cancer types that are targeted with allo-HCT such as acute myeloid leukemia (AML), lymphomas, and other hematopoietic malignancies have been shown to express high levels of Fli1 mRNA, suggesting that targeting Fli-1 in these cancer types could be beneficial in reducing their growth (18). This evidence concerns the gene FLI1 and lymphoma.